TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06730581
Drug: Utidelone Capsule 60mg/m2/d
DrugBank: Utidelone (DB17575)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60mg/m2/d, D1-D5 for 5 consecutive days, every 21 days as a treatment cycle.
Study: NCT06730581
Drug: Utidelone capsule 75mg/m2
DrugBank: Utidelone (DB17575)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 75mg/m2/d, D1-D5 for 5 consecutive days, every 21 days as a treatment cycle.
Study: NCT06730581
Drug: Utidelone Capsule
Normalized name: Utidelone
DrugBank: Utidelone (DB17575)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dosing regimens were determined based on the results of gastric and ovarian cancer dosing regimens.D1-D5 for 5 consecutive days, every 21 days as a treatment cycle.
Study: NCT06075810
Drug: MBQ-167
Normalized name: dotatate
DrugBank: Dotatate (DB14554)
Approvals — FDA: no, EMA: no, PMDA: no
Description: MBQ-167, an inhibitor of Rho GTPases Rac and Cdc42
Study: NCT05045638
Drug: Sotorasib
Normalized name: SOTORASIB
DrugBank: Sotorasib (DB15569)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Oral dose
Study: NCT05183997
Drug: Verapamil
Normalized name: Verapamil
DrugBank: Verapamil (DB00661)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: drug will be add to prolong the effect of regional block
Study: NCT05977699
Drug: salbutamol pressurized metered dose inhaler
Normalized name: salbutamol
DrugBank: Albuterol (DB01001)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: administration of 200microliters of salbutamol to reverse methacholine induced bronchoconstriction using a pressurized metered dose inhaler plus spacer
Study: NCT04748926
Drug: rilzabrutinib SAR444671
Normalized name: Rilzabrutinib
DrugBank: Rutin (DB01698)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmaceutical form: caplet Route of administration: oral
Study: NCT00002131
Drug: Vesnarinone
Normalized name: VESNARINONE
DrugBank: Vesnarinone (DB12082)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04748926
Drug: rilzabrutinib SAR444671
Normalized name: Rilzabrutinib
DrugBank: Rutin (DB01698)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmaceutical form: Oral Formulation 1 tablets Route of administration: oral
Study: NCT04748926
Drug: rilzabrutinib SAR444671
Normalized name: Rilzabrutinib
DrugBank: Rutin (DB01698)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmaceutical form: Oral Formulation 2 tablets Route of administration: oral
Study: NCT05832489
Drug: Methylphenidate immediate release 25mg
Normalized name: methylphenidate Extended Release Suspension
DrugBank: Methylphenidate (DB00422)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients will have 2 imaging sessions (MRI and EEG) after either:~* methylphenidate immediate release 25 mg~* placebo~in a cross-over design. The two imaging sessions will be separated by 11 to 87 days.
Study: NCT05602961
Drug: GLB-COV2-043
Normalized name: REGN-COV2
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: COVID-19 vaccine, administered as a booster
Study: NCT05106023
Drug: SHR-1701
Normalized name: SHR-A1904
DrugBank: SHR-A1904 (DB18702)
Approvals — FDA: no, EMA: no, PMDA: no
Description: SHR-1701 combined with temozolomide
Study: NCT05106023
Drug: Temozolomide
Normalized name: Temozolomide
DrugBank: Temozolomide (DB00853)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: SHR-1701 combined with temozolomide
Study: NCT06240403
Drug: Digoxin 0.125 MG
Normalized name: digoxin 0.125 MG
DrugBank: Digoxin (DB00390)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: One capsule containing digoxin per day for three months
Study: NCT06645522
Drug: Edaravone dexborneol
DrugBank: Borneol (DB11288)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Edaravone dexborneol injection 37.5mg (edaravone 30mg and dexborneol 7.5mg) and 100ml of 0.9% saline every 12 hours for 7 days; sequentially a sublingual dose of edaravone dexborneol 36 mg (edaravone, 30 mg; dexborneol, 6 mg) twice a day for 21 days.
Study: NCT06107205
Drug: Radicava
Normalized name: Radicava
DrugBank: Edaravone (DB12243)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 1 injection of 60 mg Radicava (reference drug R1, intravenous infusion of 60 mg administered over 60 minutes)
Study: NCT06107205
Drug: Radicava ORS
Normalized name: Radicava ORS
DrugBank: Edaravone (DB12243)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 1 single oral dose of 105 mg/5 mL Radicava ORS (reference drug R2)
Study: NCT05320198
Drug: DISC-0974
Normalized name: xylitol
DrugBank: Xylitol (DB11195)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: DISC-0974 is administered subcutaneously.
Study: NCT04856631
Drug: Toripalimab Injection
Normalized name: toripalimab Injection
DrugBank: Toripalimab (DB15043)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 240mg once per 3 weeks
Study: NCT04856631
Drug: Cetuximab Solution for infusion
Normalized name: Cetuximab
DrugBank: Cetuximab (DB00002)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: First infusion 400mg/m2，Subsequent infusions 250mg/m2。once per week
Study: NCT05665348
Drug: Ipilimumab Injection
Normalized name: ipilimumab Injection
DrugBank: Ipilimumab (DB06186)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Administration of a combine treatment by atezolizumab and bevacizumab, with addition of ipilimumab for patients enrolled in the experimental arm
Study: NCT05258799
Drug: rhTPO
Normalized name: rhTPO
DrugBank: Recombinant Human Thrombopoietin (DB16364)
Approvals — FDA: no, EMA: no, PMDA: no
Description: decitabine (15 mg/m2 daily, days 1-5); low-dose cytarabine (10 mg/m2 q12 h, days 3-9); rhTPO (15,000 U daily, days 2, 4, 6, 8, and 10-24 or until a platelet count \> 50 × 109/L was observed); aclarubicin (14 mg/m2 daily, days 3-6); and G-CSF (300 μg daily, days 2-9).
Study: NCT05665348
Drug: Atezolizumab Injection
Normalized name: atezolizumab Injection
DrugBank: Atezolizumab (DB11595)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: One of the standard treatment's product for HCC management
Study: NCT05665348
Drug: Bevacizumab
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: One of the standard treatment's product for HCC management
Study: NCT05289687
Drug: Daratumumab / Hyaluronidase Injection
Normalized name: daratumumab / hyaluronidase Injection
DrugBank: Hyaluronidase (ovine) (DB00070)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daratumumab-hyaluronidase 1800mg/ 30,000 units once weekly for 4 doses on Days 1, 8, 15, and 22
Study: NCT06025630
Drug: TUDCA
Normalized name: TUDCA
DrugBank: Tauroursodeoxycholic acid (DB08834)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endoplasmic reticulum stress will be inhibited by chronic (8 weeks) oral ingestion of the dietary supplement tauroursodeoxycholic acid (TUDCA; 1,750 mg/day)
Study: NCT05289687
Drug: Daratumumab / Hyaluronidase Injection
Normalized name: daratumumab / hyaluronidase Injection
DrugBank: Hyaluronidase (ovine) (DB00070)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients that are MRD Negative on Day 29 will receive daratumumab-hyaluronidase 1800mg/ 30,000 units once weekly for 4 doses on Days 36, 43, 50, and 57.
Study: NCT05289687
Drug: Daratumumab / Hyaluronidase Injection
Normalized name: daratumumab / hyaluronidase Injection
DrugBank: Hyaluronidase (ovine) (DB00070)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients that remain MRD positive on Day 29 will receive a combination of daratumumab-hyaluronidase 1800mg/ 30,000 units once weekly for 4 doses on Days 36, 43, 50, and 57 and chemotherapy selected from the combinations listed below:~* Cytarabine 3000 mg/m2, IV, Every 12 hours for 4 doses on Days 37 and 38~* Methotrexate 1000 mg/m2, IV, Over 24 hours on Day 36~OR~* Methotrexate, Starting dose 100 mg/m2, IV, Days 36, 46, 56~* Vincristine, 1.5 mg/m2 (2 mg cap), IV, Days 36, 46, 56~* Pegaspargase, 2000 IU/m2 (Capped at 3750 IU), IV Days 37, 57~* Methotrexate 15 mg, IT, Days 36, 56
Study: NCT05289687
Drug: Daratumumab / Hyaluronidase Injection
Normalized name: daratumumab / hyaluronidase Injection
DrugBank: Hyaluronidase (ovine) (DB00070)
Approvals — FDA: no, EMA: no, PMDA: no
Description: All patients with MRD negative response after completion of previous course are eligible for daratumumab-hyaluronidase 1800mg/ 30,000 units every 2 weeks on Days 1,15, 29, 43, 57, 71, 85, and 99 for 8 doses.
Study: NCT06731088
Drug: Midazolam
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Midazolam, a benzodiazepine sedative commonly used in ICU, acts on GABA receptors in the central nervous system to produce dose-related hypnosis, anti-pyroanxiety and anterograde amnesia, and has corresponding competitive antagonists \[8\]. It has rapid onset and short duration, but its deficiency lies in that the metabolites are still active. Thus easy accumulation, prolong the recovery time of patients
Study: NCT06731088
Drug: Remazolam besylate
Normalized name: remimazolam
DrugBank: Remimazolam (DB12404)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Remazolam besylate is a new type of benzodiazepine sedative drug metabolized by tissue esterase. It is not metabolized by liver and kidney, and is metabolized by tissue esterase rapidly in vivo to produce inactive metabolites.
Study: NCT05298176
Drug: Afatinib, Osimertinib, Carboplatin and Pemetrexed
DrugBank: Pemetrexed (DB00642)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: This study consists of 2 parts. Part 1 is defined as a first line treatment with afatinib orally (30 mg once a day) for the first 6 weeks, followed by concurrent use of afatinib (20mg once a day, part 1B) plus 2 cycles of carboplatin and pemetrexed (21 days per cycle); followed by afatinib monotherapy (30mg once a day). Part 2 comprises a 2nd line treatment with osimertinib (80 mg once daily) after failure of part 1, only in T790M positive patients for the first 6 weeks, followed by concurrent use of osimertinib (80mg once a day) plus 2 cycles of carboplatin and pemetrexed (21 days per cycle); followed by osimertinib monotherapy (80mg once a day).
Study: NCT00002030
Drug: Pentamidine isethionate
Normalized name: Pentamidine Isethionate
DrugBank: Pentamidine (DB00738)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT06201000
Drug: SGLT2 inhibitors (Dapagliflozin and Empagliflozin)
Normalized name: Fibrinolysis inhibitor
DrugBank: Aprotinin (DB06692)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 10 mg of dapagliflozin or empagliflozin
Study: NCT04764383
Drug: L-Histidine
Normalized name: L-histidine
DrugBank: Histidine (DB00117)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1000 mg capsules taken by mouth (PO) twice daily (BID).
Study: NCT04764383
Drug: Lodosyn
Normalized name: Lodosyn
DrugBank: Carbidopa (DB00190)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 50 mg capsules taken PO BID.
Study: NCT06083844
Drug: Pembrolizumab
Normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Given by IV (vein)
Study: NCT06083844
Drug: Bevacizumab
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Given by IV (vein)
Study: NCT04907344
Drug: Camrelizumab
Normalized name: Camrelizumab
DrugBank: Camrelizumab (DB14776)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV infusion
Study: NCT04907344
Drug: Nab-Paclitaxel
Normalized name: NAB-PACLITAXEL COMPONENT PACLITAXEL
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: IV infusion
Study: NCT04907344
Drug: Carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: IV infusion
Study: NCT05473468
Drug: Famitinib
Normalized name: Famitinib
DrugBank: Famitinib (DB11741)
Approvals — FDA: no, EMA: no, PMDA: no
Description: a single oral dose of \[14C\]famitinib (25 mg/150 uCi suspension)
Study: NCT04856397
Drug: Intravitreal Implant in Applicator
Normalized name: Dexamethasone Intravitreal Implant
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dexamethasone intravitreal implant
Study: NCT04856397
Drug: Eylea
Normalized name: Eylea
DrugBank: Aflibercept (DB08885)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: anti-VEGF medication
Study: NCT05167331
Drug: Nitrous Oxide inhalation
Normalized name: nitrous oxide Inhalant Product
DrugBank: Nitrous oxide (DB06690)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: use of Nitrous Oxide inhalation on children's anxiety during a dental treatment
Study: NCT06270017
Drug: Chemotherapy drug
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: rsponse evaluation in zebrafish embryo model
Study: NCT05306223
Drug: Bedaquiline
Normalized name: Bedaquiline
DrugBank: Bedaquiline (DB08903)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Bedaquiline uncoated tablets will be administered orally.
Study: NCT05306223
Drug: Levofloxacin
Normalized name: Levofloxacin
DrugBank: Levofloxacin (DB01137)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Levofloxacin filmcoated will be administered orally
Study: NCT05306223
Drug: Linezolid
Normalized name: Linezolid
DrugBank: Linezolid (DB00601)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Linezolid tablets will be administered orally
Study: NCT05306223
Drug: Cycloserine
Normalized name: Cycloserine
DrugBank: Cycloserine (DB00260)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cycloserine capsules will be administered orally.
Study: NCT05306223
Drug: Clofazimine
Normalized name: Clofazimine
DrugBank: Clofazimine (DB00845)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clofazimine capsules will be administered orally.
Study: NCT05306223
Drug: Pyrazinamide
Normalized name: Pyrazinamide
DrugBank: Pyrazinamide (DB00339)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pyrazinamide tablets will be administered orally.
Study: NCT05306223
Drug: Protionamide
Normalized name: protionamide
DrugBank: Protionamide (DB12667)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Protionamide enteric-coated tablets will be administered orally.
Study: NCT05746676
Drug: Insulin
Normalized name: Insulin
DrugBank: Insulin human (DB00030)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: in treatment of periodontal defects
Study: NCT05746676
Drug: Hyaluronic acid
Normalized name: hyaluronic acid
DrugBank: Hyaluronic acid (DB08818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: in treatment of periodontal defects
Study: NCT05104424
Drug: Insulin aspart
Normalized name: Insulin Aspart
DrugBank: Insulin aspart (DB01306)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: intranasal rapid insulin 40 I.U as 0.1 ml as 2 puff at each nostril once weekly for 8 weeks zinc 50 mg orally daily Gabapentin 300 mg once daily for 1 month small ice cube at mouth before meals thrice daily
Study: NCT06448195
Drug: Polyethylene Glycol Somatropin (rDNA origin) Injection
Normalized name: Polyethylene Glycol
DrugBank: Polyethylene glycol (DB09287)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Specification: 54IU/9.0mg/1.0ml/ bottle Dosage form: injection; Dose: 1mg/ week. Subcutaneous injection (upper arm, thigh or abdomen periumbilical) for a total course of 6 months, a total of 3 bottles per patient
Study: NCT06088082
Drug: Bupivacaine Hydrochloride
Normalized name: Bupivacaine Hydrochloride
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients will be randomly assigned to receive a TAP and PRS blocks with 34 mL of 0.25% bupivacaine (study group) or standard hospital analgesia protocol (control group).
Study: NCT05127824
Drug: Cabozantinib
Normalized name: Cabozantinib
DrugBank: Cabozantinib (DB08875)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Cabozantinib tablets are supplied as film coated tablets containing cabozantinib malate equivalent to 20 mg and 60 mg of cabozantinib and contain microcrystalline cellulose, lactose anhydrous, hydoxypropyl cellulose, croscarmellose sodium, colloidal silicon dioxide, magnesium stearate and Opadry® yellow. The 60 mg tablets are oval and the 20 mg tablets are round. Doses of 40 mg will comprise two 20-mg tablets.
Study: NCT06095492
Drug: Empagliflozin 25 MG
Normalized name: empagliflozin 25 MG
DrugBank: Empagliflozin (DB09038)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Patient will get Empagliflozin 25
Study: NCT06095492
Drug: Linagliptin
Normalized name: Linagliptin
DrugBank: Linagliptin (DB08882)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: linagliptin 5 mg once a day
Study: NCT06701149
Drug: Rademikibart injection
Normalized name: Rademikibart
DrugBank: Rademikibart (DB18995)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg administered subcutaneously on the first day
Study: NCT06701149
Drug: CBP-201 injection
Normalized name: CBPC
DrugBank: Carbenicillin (DB00578)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 300 mg administered subcutaneously on the first day
Study: NCT06634199
Drug: Durvalumab
Normalized name: Durvalumab
DrugBank: Durvalumab (DB11714)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Chemo-radiotherapy + Durvalumab for non-resectable stage III NSCLC patients according to clinical practice of each participant hospital
Study: NCT06716970
Drug: Sacubitril/valsartan 200mg
DrugBank: Valsartan (DB00177)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Sacubitril/valsartan 200mg QD
Study: NCT06716970
Drug: Sacubitril/valsartan 200mg placebo
DrugBank: Valsartan (DB00177)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Matching placebo of Sacubitril/valsartan 200mg QD
Study: NCT05022628
Drug: Donafenib
Normalized name: DONAFENIB
DrugBank: CM-4307 (DB15414)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Donafenib treatment regimen.~1. Donafenib started on the day of the first radiation treatment.~2. starting dose 0.2 g bid twice daily orally on an empty stomach (1 hour before or 2 hours after a meal).~3. Surgery after at least 1 week off Donafinil; resume Donafinil dosing as soon as possible after postoperative wound healing until any of the following occurs, whichever occurs first: (i) the subject develops an intolerable toxic reaction that does not resolve after dose adjustment (see 5.3 for details); (ii) 12 months of postoperative dosing; (iii) the subject has the first imaging-confirmed recurrence of disease or withdraws from the study (whichever occurs first).~4. Dose adjustment/withdrawal: Subjects are allowed up to 2 dose adjustments if they experience an adverse event related to the trial drug during treatment.
Study: NCT06721286
Drug: Teripalimab
Normalized name: Toripalimab
DrugBank: Toripalimab (DB15043)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 240mg intravenous injection, D1, q3w, for 9 weeks (3 cycles)
Study: NCT06721286
Drug: Gemcitabine + Cisplatin
Normalized name: Cisplatin
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Gemcitabine 1000mg/m2 + cisplatin 25mg/m2, D1\&D8, q3w, for 9 weeks (3 cycles)
Study: NCT05602207
Drug: Abrocitinib
Normalized name: Abrocitinib
DrugBank: Abrocitinib (DB14973)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 100 mg Abrocitinib once daily (QD) for 12 weeks
Study: NCT06719934
Drug: Dienogest 2 mg orally
Normalized name: dienogest 2 MG
DrugBank: Dienogest (DB09123)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 2 mg Dienogest orally
Study: NCT00055510
Drug: BO-653
Normalized name: BO-653
DrugBank: BO-653 (DB19216)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT06719986
Drug: Nalmefene HCl injection
Normalized name: nalmefene Injection
DrugBank: Nalmefene (DB06230)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Nalmefene Hydrochloride injection 1.5 mg for intramuscular (IM) administration
Study: NCT05658887
Drug: Gabapentin
Normalized name: Gabapentin
DrugBank: Gabapentin (DB00996)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: One dose of preoperative gabapentin 300 mg prior to vaginal apical support procedure
Study: NCT05658887
Drug: Gabapentin Placebo
DrugBank: Gabapentin (DB00996)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Gabapentin Placebo
Study: NCT06719986
Drug: Naloxone HCl intranasal
Normalized name: Naloxone Hydrochloride
DrugBank: Naloxone (DB01183)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Naloxone 4 mg for intranasal (IN) administration
Study: NCT06720220
Drug: Dexmedetomidine Hydrochloride
Normalized name: Dexmedetomidine Hydrochloride
DrugBank: Dexmedetomidine (DB00633)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: procedural sedation by I.V. infusion of dexmedetomidine. It was prepared as 200 ug (2 ml) of dexmedetomidine added to 48 ml of 0.9% saline.~A loading dose of dexmedetomidine 0.5 to 1 ug/kg was given over 10- 20 minutes, followed by 0.2-0.7 ug/kg/hr as a continuous infusion by a syringe pump. During the dexmedetomidine infusion, a spontaneous respiratory pattern was maintained, and the level of sedation achieved to a point of semi-sleep but responds to commands (equivalent to Modified Ramsay Sedation Scale score of 3).
Study: NCT06720025
Drug: SAL-0951 tablets
Normalized name: salicylate
DrugBank: Bismuth subsalicylate (DB01294)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: initial phase：4mg QD subsequent phase：1mg～8mg QD，adjust the dose based on hemoglobin concentration level every 4 weeks
Study: NCT06720025
Drug: rHuEPO injection
Normalized name: GlycoPEGylated™rHuEPO
DrugBank: NE-180 (DB05619)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Initial based on the original rHuEPO dose adjust the dose based on hemoglobin concentration level every 4 weeks
Study: NCT05266963
Drug: CREON
Normalized name: Creon
DrugBank: Pancrelipase amylase (DB11065)
Approvals — FDA: no, EMA: no, PMDA: no
Description: The study will enroll 6-10 adult subjects with T1D who will receive both pancreatic enzyme replacement (CREON) or placebo each for 7 days in a random order. The effect of the intervention will be monitored by continuous glucose monitoring, diet recording, capsule counts, a mixed-meal tolerance test, and a survey to assess symptoms of PEI. This study design will allow for estimation of the effect of pancreatic enzyme replacement on the measured parameters.
Study: NCT04921384
Drug: Eptinezumab
Normalized name: Eptinezumab
DrugBank: Eptinezumab (DB14040)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Solution for infusion, intravenously
Study: NCT03401294
Drug: FOLFOXIRI and Bevacizumab
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Every 2 week for a total of 12 cycles
Study: NCT05567185
Drug: Erdafitinib Intravesical Delivery System
Normalized name: erdafitinib
DrugBank: Erdafitinib (DB12147)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Erdafitinib intravesical delivery system will be administered.
Study: NCT05954780
Drug: Selinexor
Normalized name: Selinexor
DrugBank: Selinexor (DB11942)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Selinexor/bortezomib/dexamethasone according to Nexpovio® SmPC
Study: NCT05450744
Drug: 131I-IPA
Normalized name: IPA
DrugBank: Riboprine (DB11933)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 131I-IPA: injection/solution administrated intravenously via infusion in ascending doses 18F-FET: injection/solution administrated intravenously
Study: NCT05735275
Drug: SHR-A2102
Normalized name: SHR-A1904
DrugBank: SHR-A1904 (DB18702)
Approvals — FDA: no, EMA: no, PMDA: no
Description: All participants receive SHR-A2102 alone.
Study: NCT04372108
Drug: Ustekinumab
Normalized name: Ustekinumab
DrugBank: Ustekinumab (DB05679)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Participants who are new users of ustekunumab will be included in the cohort. No study treatment will be administered as a part of this study.
Study: NCT06344949
Drug: Ciprofol
Normalized name: fluocinolone
DrugBank: Fluocinolone (DB12553)
Approvals — FDA: no, EMA: no, PMDA: no
Description: The sedation before tracheal intubation with Ciprofol